A practical reference on systematic review: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-12 and is reviewed periodically as new material appears.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Identity and purity are normally confirmed by reversed-phase high-performance liquid chromatography and mass spectrometry. The expected mass for the acetylated 28-residue peptide is close to 3108 daltons, and a mass shift indicates a modification or truncation. Peptide mapping after enzymatic digestion can resolve sequence-level questions. Counter-ion content, water content, and residual solvents are separate quality attributes that a certificate of analysis may or may not report. Aggregation is monitored by size-exclusion chromatography when relevant.
Thymosin alpha-1 is supplied as a lyophilized powder in most research settings. The solid dissolves readily in water and in common aqueous buffers, and it is typically reconstituted shortly before use. Solutions are clear and colourless at ordinary working concentrations. Because the peptide is hygroscopic, weighing and reconstitution are usually performed with minimal exposure to ambient air. Aliquots are prepared to avoid repeated freeze-thaw cycles, and working solutions are kept cold.
Long-term storage is generally at minus twenty degrees Celsius or colder, preferably desiccated and protected from light. Lyophilized material is more stable than reconstituted solution, which degrades faster at room temperature. Stability depends on pH, ionic strength, and the presence of oxidising agents. Published stability data for the peptide are limited, so storage claims in catalogues should be treated as general guidance rather than measured guarantees. Freeze-thaw cycles are kept to a minimum.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Laboratory supplies of the peptide usually arrive as a lyophilized powder in sealed vials. The powder is hygroscopic, so a vial should be allowed to reach room temperature before it is opened to prevent condensation on the contents. Weighing and transfer are best performed in a low-humidity environment with clean tools. Once dissolved, the solution should be mixed gently rather than vortexed, because foaming and shear can reduce recovery of the peptide.
Storage recommendations center on low temperature, dryness, and protection from repeated freezing and thawing. The intact powder is commonly held at 20 degrees below zero Celsius or colder, while a working solution is divided into single-use aliquots to limit freeze-thaw cycles. Buffered saline or phosphate-buffered saline at neutral pH is frequently used as a diluent. Light sensitivity is not well documented, yet amber vials or foil wrapping are common practice for long-term storage of peptide stocks.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Given the overwhelming Allied air superiority, the Luftwaffe put its effort into the development of aircraft of such high performance that they could operate with impunity, but which also made bomber attack much more difficult, merely from the flight velocities they achieved. Foremost among these were the Messerschmitt Me 163B point-defense rocket interceptors, which started their operations with JG 400 near the end of July 1944, and the longer-endurance Messerschmitt Me 262A jet fighter, first flying with the Gruppe-strength Kommando Nowotny unit by the end of September 1944. In action, the Me 163 proved to be more dangerous to the Luftwaffe than to the Allies and was never a serious threat. The Me 262A was a serious threat, but attacks on their airfields neutralized them. The pioneering Junkers Jumo 004 axial-flow jet engines of the Me 262As needed careful nursing by their pilots, and these aircraft were particularly vulnerable during takeoff and landing. Lt. Chuck Yeager of the 357th Fighter Group was one of the first American pilots to shoot down an Me 262, which he caught during its landing approach. On 7 October 1944, Lt. Urban L. Drew of the 361st Fighter Group shot down two Me 262s that were taking off, while on the same day, Lt. Col. Hubert Zemke, who had transferred to the Mustang-equipped 479th Fighter Group, shot down what he thought was a Bf 109, only to have his gun camera film reveal that it may have been an Me 262. On 25 February 1945, Mustangs of the 55th Fighter Group surprised an entire Staffel of Me 262As at takeoff and destroyed six jets.
There are four types of minicore myopathy Classical type (75% cases) The usual presentation is in infancy or childhood with hypotonia or proximal weakness. This weakness tends to affect the shoulder girdle and the inner thigh. The other main features are
The Scoville scale is a measure of the hotness of a chili pepper. It is the degree of dilution in sugar water of a specific chili pepper extract when a panel of 5 tasters can no longer detect its "heat". Pure capsaicin (the chemical responsible for the "heat") has 16 million Scoville heat units.
Flap endonuclease (FEN) is an endonuclease that catalyzes structure-specific cleavage. This cleavage is highly sensitive to mismatches and can be used to interrogate SNPs with a high degree of specificity In the basic Invader assay, a FEN called cleavase is combined with two specific oligonucleotide probes, that together with the target DNA, can form a tripartite structure recognized by cleavase. The first probe, called the Invader oligonucleotide is complementary to the 3’ end of the target DNA. The last base of the Invader oligonucleotide is a non-matching base that overlaps the SNP nucleotide in the target DNA. The second probe is an allele-specific probe which is complementary to the 5’ end of the target DNA, but also extends past the 3’ side of the SNP nucleotide. The allele-specific probe will contain a base complementary to the SNP nucleotide. If the target DNA contains the desired allele, the Invader and allele-specific probes will bind to the target DNA forming the tripartite structure. This structure is recognized by cleavase, which will cleave and release the 3’ end of the allele-specific probe. If the SNP nucleotide in the target DNA is not complementary to the allele-specific probe, the correct tripartite structure is not formed and no cleavage occurs. The Invader assay is usually coupled with fluorescence resonance energy transfer (FRET) system to detect the cleavage event. In this setup, a quencher molecule is attached to the 3’ end and a fluorophore is attached to the 5’ end of the allele-specific probe.
In June 2023, Moore released $5 million in funding from the American Rescue Plan Act of 2021 toward youth intervention efforts to deter violent crime around the state. In July 2023, following mass shootings in Baltimore and Salisbury that left a combined three dead and 34 injured, Moore released a statement expressing his condolences and spoke in support of gun violence prevention efforts in Baltimore. He ruled out calls to form a special session to pass legislation to address gun violence, saying it was not needed, but said he supported increased policing and longer sentences for repeat violent offenders. In January 2024, Moore introduced three bills aimed at improving public safety, including one to create apprenticeships in public safety to increase law enforcement retention and another to compensate victims of crime. He also expressed support for lengthening probation periods for violent juvenile offenders and increasing the severity for gun crimes from misdemeanors to felonies, and another bill to restrict sex offenders' ability to earn "good time" credits that reduce their sentence following the murder of Pava LaPere. He also supported a bill that would allow minors to be charged with certain crimes and enable courts to extend probation limits for juveniles. Moore signed all three bills into law in May 2024. In October 2024, after a Howard High School student with a prior criminal record was charged with first-degree murder, Moore ordered a review of how state agencies share information about public school students with violent criminal records.
Sources: en.wikipedia.org
=== Physicians and researchers === Among the renowned individuals who have worked with the University of Pittsburgh's medical center through its history are Jonas Salk who developed the polio vaccine while at the University of Pittsburgh, pediatric psychoanalyst Benjamin Spock, Peter Safar who pioneered CPR and the world's first intensive care training program at the medical center, and surgeon Thomas Starzl who perfected organ transplantation there. Other doctors include pathologist Maud Menten who is famous for her contributions to enzyme kinetics, leading orthopedic surgeon and sports medicine expert Freddie Fu, pioneering immunologist Niels Kaj Jerne, forensic pathologist and Allegheny County Coroner Cyril Wecht, Vitamin C's discoverer Charles Glen King, pediatrician Jack Paradise, leading head and neck cancer surgeon and otolaryngologist Eugene Nicholas Myers, laparoscopic liver resection pioneer David Geller, breast cancer treatment pioneer Bernard Fisher, and virologists Patrick Moore and Yuan Chang, who co-discovered Kaposi's sarcoma-associated herpesvirus.
==== Shortness of breath ==== Opioids may help with shortness of breath particularly in advanced diseases such as cancer and COPD. However, findings from two recent systematic reviews of the literature found that opioids were not necessarily more effective in treating shortness of breath in patients who have advanced cancer.
== Contraindications == Selegiline is contraindicated with serotonergic antidepressants including selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs), and tricyclic antidepressants (TCAs), with serotonergic opioids like meperidine, tramadol, and methadone, with other monoamine oxidase inhibitors (MAOIs) such as linezolid, phenelzine, and tranylcypromine, and with dextromethorphan, St. John's wort, cyclobenzaprine, pentazocine, propoxyphene, and carbamazepine. Combination of selegiline with serotonergic agents may cause serotonin syndrome, while combination of selegiline with adrenergic or sympathomimetic agents like ephedrine or amphetamines may cause hypertensive crisis. Long washout periods are required before starting and stopping these medications with discontinuation or initiation of selegiline. Consumption of tyramine-rich foods can result in hypertensive crisis with selegiline, also known as the "cheese effect" or "cheese reaction" due to the high amounts of tyramine present in some cheeses. Examples of other foods that may have high amounts of tyramine and similar substances include yeast products, chicken liver, snails, pickled herring, red wines, some beers, canned figs, broad beans, chocolate, and cream products. The preceding drug and food contraindications are dependent on selegiline dose and route, and hence are not necessarily absolute contraindications.
24 May – Researchers from the Chinese Academy of Sciences report tuning of the Casimir effect using magnetic fields. 30 May – NASA reports that the James Webb Space Telescope has discovered JADES-GS-z14-0, the most distant known galaxy, which existed only 290 million years after the Big Bang. Its redshift of 14.32 exceeds the previous record of 13.2, set by JADES-GS-z13-0. 31 May – Biologists report that Tmesipteris oblanceolata, a fern ally plant, was found to contain the largest known genome. Promising results of health and medical research are reported: a mRNA vaccine-like immunotherapy against brain cancer tested in a preliminary small trial (1 May), ferrets-tested mRNA vaccine against the clade 2.3.4.4b H5 bird flu amid concerning developments of the 2020–2025 H5N1 outbreak (23 May), mice-tested antibiotic lolamicin specific to Gram-negative bacteria that spares the gut microbiome (29 May).
Sources: en.wikipedia.org
Nick Fury: Agent of S.H.I.E.L.D. (stylized as Nick Fury: Agent of SHIELD and Nick Fury: Agent of Shield) is a 1998 American television superhero film based on the Marvel Comics character Nick Fury. It was first broadcast on May 26, 1998, on Fox, intended to be a backdoor pilot for a possible new TV series. Written by David Goyer, and directed by Rod Hardy, the film had a $6 million production budget. It stars David Hasselhoff as Fury, a retired super spy who is approached to return to duty to take down the terrorist organization HYDRA, who threaten to attack Manhattan with a pathogen they have reconstituted known as the Death's Head virus. Lisa Rinna plays Contessa Valentina "Val" Allegra de Fontaine, and Sandra Hess plays Andrea von Strucker/Viper. It was released on DVD on September 30, 2008. The film was met with a largely negative reception.
== Chemistry == Pure acetylcysteine is in a solid state at room temperature, appearing as a white crystalline powder or granules. The solid form of acetylcysteine is stable under normal conditions, but it can undergo oxidation if exposed to air or moisture over time, leading to the formation of its dimeric form, diacetylcysteine, which can have different properties. Acetylcysteine is highly hygroscopic, i.e., it absorbs moisture if exposed to open air. Acetylcysteine can sometimes appear as a light yellow cast powder instead of pure white due to oxidation. The sulfur-containing amino acids, like cysteine, are more easily oxidized than other amino acids. When exposed to air or moisture, acetylcysteine can oxidize, leading to a slight yellowish tint. Acetylcysteine in a form of a white or white with light yellow cast powder has a pKa of 3.14 (carboxyl group) and 9.5 (thiol) at 30 °C. N-acetyl-L-cysteine is soluble in water and alcohol, and practically insoluble in chloroform and ether. Acetylcysteine dissolves readily in water, forming a colorless solution. The pH of a 1% acetylcysteine solution in water typically ranges between 2.0 and 2.8. Solutions with higher concentrations of acetylcysteine have lower pH. Aqueous solutions of acetylcysteine are compatible with 0.9% sodium chloride solution; compatibility with 5% and 10% glucose solutions is also good. As for photochemical stability, acetylcysteine in dry powder form is relatively stable and does not degrade quickly when exposed to light, but in aqueous solution, acetylcysteine can degrade when exposed to sunlight.
=== Other === Flunitrazepam impairs cognitive functions. This may appear as lack of concentration, confusion and anterograde amnesia—the inability to create memories while under the influence. It can be described as a hangover-like effect which can persist to the next day. It also impairs psychomotor functions similar to other benzodiazepines and nonbenzodiazepine hypnotic drugs; falls and hip fractures were frequently reported. The combination with alcohol increases these impairments. Partial, but incomplete tolerance develops to these impairments. Other adverse effects include:
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
Lyophilized powder is normally kept at minus twenty degrees Celsius or below, in a sealed container, desiccated and away from light. Reconstituted solutions are less stable and are usually refrigerated and used quickly. Repeated temperature cycling should be avoided.